The Severity of SARS-CoV-2 Infection among Patients with Multiple Sclerosis

Document Type : Original Article


1 Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of MPH, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran


Background: Neurological disability associated with multiple sclerosis and immunosuppressive or immunomodulatory therapy which is administered for it may increase the risk of SARS-CoV-2 infection and its morbidity/mortality.
In this study, we evaluated the severity of SARS-CoV-2 infection in patients with multiple sclerosis based on their demographic and disease data.
Methods: A total of 1361 multiple sclerosis patients from Fars province were interviewed by phone from April 3 to June 20, 2020. Basic demographic data, information about their disease and any symptoms or laboratory results relevant to COVID-19 were gathered.
Results: Among the studied patients, 68 ones (5%) were COVID-19 suspected cases and 8 ones (0.58%) were in the confirmed group. Five cases in the confirmed group needed hospitalization. Two patients died while both of them were taking rituximab. The frequency rate of suspected cases with RRMS was 57 (87.7%), followed by 5 (7.7%) PPMS and 2 (3.1%) CIS. In the confirmed group, 25% used corticosteroid drug and 50% were on rituximab; moreover, 62.5% of the confirmed cases had a high disability level and needed assistance to walk. In whole, 36.8% of the suspected and 25% of the confirmed cases were on IFN-β1; eventually, all of them recovered well from COVID-19 infection.
Conclusion: In the present study, the rate of developing COVID-19 in multiple sclerosis patients was similar to the general population and most of patients with multiple sclerosis recovered from COVID-19 without referral to a medical specialist.


  1. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers 2018; 4(1):43. doi: 10.1038/s41572-018-0041-4.
  2. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol 2019; 77(2):184-91. doi: 10.1001/jamaneurol.2019.3365.
  3. Wijnands JM, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry 2018; 89(10):1050-6. doi: 10.1136/jnnp-2017-317493.
  4. Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 2016; 12(4):217-33. doi: 10.1038/nrneurol.2016.21.
  5. Esai Selvan M. Risk factors for death from COVID-19. Nat Rev Immunol 2020; 20(7):407. doi: 10.1038/s41577-020-0351-0.
  6. Gemcioglu E, Davutoglu M, Ozdemir EE, Erden A. Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? Mult Scler Relat Disord 2020; 42:102196. doi: 10.1016/j.msard.2020.102196.
  7. Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 2020; 178:104791. doi: 10.1016/j.antiviral.2020.104791.
  8. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1):222. doi: 10.1038/s41467-019-13940-6.
  9. Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD. SARS-CoV-2 is sensitive to type I interferon pretreatment. BioRxiv doi: 10.1101/2020.03.07.982264.
  10. Cristiano E, Patrucco L, Rojas JI, Nunez S. Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina. Mult Scler Relat Disord 2020; 44:102307. doi: 10.1016/j.msard.2020.102307.
  11. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 2020; 43:102195. doi: 10.1016/j.msard.2020.102195.
  12. Sormani MP, Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis. Lancet Neurol 2020; 19(6):481-2. doi: 10.1016/S1474-4422(20)30147-2.
  13. Fan M, Qiu W, Bu B, Xu Y, Yang H, Huang D, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2020; 7(5): e787. doi: 10.1212/NXI.0000000000000787.
  14. Montero-Escribano P, Matias-Guiu J, Gomez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain. Mult Scler Relat Disord 2020; 42:102185. doi: 10.1016/j.msard.2020.102185.
  15. Azami M, YektaKooshali MH, Shohani M, Khorshidi A, Mahmudi L. Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis. PLoS One 2019; 14(4):e0214738. doi: 10.1371/journal.pone.0214738.
  16. Abdi M. Coronavirus disease 2019 (COVID-19) outbreak in Iran: Actions and problems. Infect Control Hosp Epidemiol 2020; 41(6):754-5. doi: 10.1017/ice.2020.86.
  17. Devi S. COVID-19 resurgence in Iran. Lancet 2020; 395(10241):1896. doi: 10.1016/S0140-6736(20)31407-0.
  18. Lu M. The Front Line: Visualizing the Occupations with the Highest COVID-19 Risk. Science & Technical Information 2020; .
  19. Wijnands JM, Kingwell E, Zhu F, Zhao Y, Fisk JD, Evans C, et al. Infection-related health care utilization among people with and without multiple sclerosis. Mult Scler 2017; 23(11):1506-16. doi: 10.1177/1352458516681198.
  20. Signorelli C, Scognamiglio T, Odone A. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Biomed 2020; 91(3-S):175-9. doi: 10.23750/abm.v91i3-S.9511.
  21. Sahraian MA, Azimi A, Navardi S, Ala S, Naser Moghadasi A. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 2020; 46:102472. doi: 10.1016/j.msard.2020.102472.
  22. Oksuzyan A, Juel K, Vaupel JW, Christensen K. Men: good health and high mortality. Sex differences in health and aging. Aging Clin Exp Res 2008; 20(2):91-102. doi: 10.1007/BF03324754.
  23. Sahraian MA, Gheini MR, Rezaeimanesh N, Ghajarzadeh M, Naser Moghadasi A. Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran. Mult Scler Relat Disord 2020; 42:102193. doi: 10.1016/j.msard.2020.102193.
  24. Akbari A, Emami A, Javanmardi F, Pirbonyeh N, Fadakar N. Early Epidemiological analysis of CoVID-19: Firstreport from South of Iran. Research Square 2020. doi: 10.21203/
  25. Marrie RA, Elliott L, Marriott J, Cossoy M, Blanchard J, Leung S, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology 2015; 85(3):240-7. doi: 10.1212/WNL.0000000000001718.
  26. Marrie RA, Elliott L, Marriott J, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology 2015; 84(4):350-8. doi: 10.1212/WNL.0000000000001187.
  27. Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol 2020; 146(1):211-13. doi: 10.1016/j.jaci.2020.04.013.
  28. Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol 2019; 20(12):1574-83. doi: 10.1038/s41590-019-0466-2.